Artykuły w czasopismach na temat „Metastatic papillary renal-Cell cancer”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Metastatic papillary renal-Cell cancer”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Sidana, Abhinav, Amit L. Jain, Meet Kadakia, Spencer Krane, Julia C. Friend, Akhil Muthigi, Martha Ninos, Joanna H. Shih i Ramaprasad Srinivasan. "Predictors of mortality in metastatic papillary renal cell cancer." Journal of Clinical Oncology 35, nr 6_suppl (20.02.2017): 509. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.509.
Pełny tekst źródłaCarlo, Maria Isabel, Nabeela Khan, Yingbei Chen, James Hsieh, A. Ari Hakimi, Chung-Han Lee, Darren R. Feldman, Robert J. Motzer i Martin Henner Voss. "The genomic landscape of metastatic non-clear cell renal cell carcinoma." Journal of Clinical Oncology 35, nr 6_suppl (20.02.2017): 474. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.474.
Pełny tekst źródłaGraham, Jeffrey, Connor Wells, Frede Donskov, Jae-Lyun Lee, Anna Paola Fraccon, Felice Pasini, Camillo Porta i in. "Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)." Journal of Clinical Oncology 36, nr 6_suppl (20.02.2018): 581. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.581.
Pełny tekst źródłaDudani, Shaan, Guillermo de Velasco, Connor Wells, Chun Loo Gan, Frede Donskov, Camillo Porta, Anna Fraccon i in. "Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): 5071. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5071.
Pełny tekst źródłaMotzer, Robert J., Jennifer Bacik, Tania Mariani, Paul Russo, Madhu Mazumdar i Victor Reuter. "Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non–Clear-Cell Histology". Journal of Clinical Oncology 20, nr 9 (1.05.2002): 2376–81. http://dx.doi.org/10.1200/jco.2002.11.123.
Pełny tekst źródłaRonnen, Ellen A., G. Varuni Kondagunta, Nicole Ishill, Lesley Spodek, Paul Russo, Victor Reuter, Jennifer Bacik i Robert J. Motzer. "Treatment outcome for metastatic papillary renal cell carcinoma patients". Cancer 107, nr 11 (2006): 2617–21. http://dx.doi.org/10.1002/cncr.22340.
Pełny tekst źródłaElabbady, Ahmed, Ryan Boudreau i Vahid Mehrnoush. "Rapid metachronous bladder metastasis of type 2 papillary renal cell carcinoma". Archive of Clinical Cases 10, nr 2 (18.05.2023): 93–96. http://dx.doi.org/10.22551/2023.39.1002.10249.
Pełny tekst źródłaSteiner, T., J. Roigas, H. Kirchner, C. Doehn, H. Heynemann, M. Siebels, S. Loening i in. "Clinical course of patients with metastatic papillary renal cell carcinoma". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 14591. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.14591.
Pełny tekst źródłaYonese, Ichiro, Masaya Ito, Kosuke Takemura, Takao Kamai i Fumitaka Koga. "A Case of Metastatic Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome-Associated Renal Cell Carcinoma Treated with a Sequence of Axitinib and Nivolumab Following Cytoreductive Nephrectomy". Journal of Kidney Cancer and VHL 7, nr 2 (20.07.2020): 6–10. http://dx.doi.org/10.15586/jkcvhl.2020.148.
Pełny tekst źródłaSchrader, A. J., S. Rauer-Bruening, P. J. Olbert, A. Hegele, J. Rustemeier i R. Hofmann. "Incidence and long term prognosis of papillary renal cell carcinoma". Journal of Clinical Oncology 27, nr 15_suppl (20.05.2009): e16020-e16020. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e16020.
Pełny tekst źródłaFriend, Julia C., Daniel Su, Rashmi Thimmapuram, James Peterson, Geri Hawks, Martha Ninos, W. Marston Linehan i Ramaprasad Srinivasan. "Malignant ascites as a manifestation of advanced papillary renal cell cancer (pRCC)." Journal of Clinical Oncology 33, nr 7_suppl (1.03.2015): 465. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.465.
Pełny tekst źródłaWells, J. Connor, Frede Donskov, Anna Paola Fraccon, Felice Pasini, Georg A. Bjarnason, Jennifer J. Knox, Benoit Beuselinck i in. "Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC)." Journal of Clinical Oncology 34, nr 15_suppl (20.05.2016): 4554. http://dx.doi.org/10.1200/jco.2016.34.15_suppl.4554.
Pełny tekst źródłaSomorácz, Áron, Levente Kuthi, Tamás Micsik, Alex Jenei, Adrienn Hajdu, Brigitta Vrabély, Erzsébet Rásó i in. "Renal Cell Carcinoma with Clear Cell Papillary Features: Perspectives of a Differential Diagnosis". Pathology & Oncology Research 26, nr 3 (26.10.2019): 1767–76. http://dx.doi.org/10.1007/s12253-019-00757-3.
Pełny tekst źródłaBarua, Sasanka K., Sarbartha K. Pratihar, Pranab K. Kaman, Atul Garg, Rajeev T. P., Saumar J. Baruah, Puskal K. Bagchi, Debanga Sarma i Mandeep Phukan. "Cervical lymphadenopathy as initial presentation of genito-urinary cancer". International Journal of Otorhinolaryngology and Head and Neck Surgery 5, nr 6 (23.10.2019): 1739. http://dx.doi.org/10.18203/issn.2454-5929.ijohns20194964.
Pełny tekst źródłaStenman, Maria, Andreas Demetrios Nearchou, Per Sandström, Magnus Lindskog i Ulrika Harmenberg. "Metastatic papillary renal cell carcinoma: A retrospective study from two large academic centers in Sweden." Journal of Clinical Oncology 34, nr 2_suppl (10.01.2016): 535. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.535.
Pełny tekst źródłaPark, Sang Hyun, Taek Sang Kim, Jae Young Joung, Sung Han Kim i Jinsoo Chung. "Postoperative long-term prognosis of localized renal cell carcinoma after partial or radical nephrectomy: Analysis of cancer metastasis and deaths during a more than five-year follow-up." Journal of Clinical Oncology 37, nr 7_suppl (1.03.2019): 604. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.604.
Pełny tekst źródłaZielli, Teresa, Letizia Gnetti i Sebastiano Buti. "Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report". Tumori Journal 106, nr 6 (27.05.2020): NP79—NP83. http://dx.doi.org/10.1177/0300891620924472.
Pełny tekst źródłaArmstrong, Andrew J., Susan Halabi, Tim Eisen, Walter Michael Stadler, Robert R. Jones, Ulka N. Vaishampayan, Jorge A. Garcia i in. "ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma." Journal of Clinical Oncology 31, nr 15_suppl (20.05.2013): TPS4590. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps4590.
Pełny tekst źródłaShuch, Brian, Lambros Stamatakis, Clara Chen, Rabindra Gautam, Maria Merino, Peter L. Choyke, W. Marston Linehan i Ramaprasad Srinivasan. "Utility of 2-(18F) fluoro-2 deoxy-D-glucose PET/CT in advanced papillary renal cell carcinoma." Journal of Clinical Oncology 32, nr 4_suppl (1.02.2014): 419. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.419.
Pełny tekst źródłaDidwaniya, N., R. J. Edmonds, X. Fang, P. T. Silberstein i S. Subbiah. "Survival outcomes in metastatic renal carcinoma based on histological subtypes: SEER database analysis." Journal of Clinical Oncology 29, nr 7_suppl (1.03.2011): 381. http://dx.doi.org/10.1200/jco.2011.29.7_suppl.381.
Pełny tekst źródłade Vries-Brilland, Manon, Nathalie Rioux-Leclercq, Maxime Meylan, Jonathan Dauvé, Christophe Passot, Elena Spirina-Menand, Ronan Flippot i in. "Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma". Journal for ImmunoTherapy of Cancer 11, nr 11 (listopad 2023): e006885. http://dx.doi.org/10.1136/jitc-2023-006885.
Pełny tekst źródłaMcKay, Rana R., Pedro C. Barata, Andrew Elliott, Mehmet Asim Bilen, Earle F. Burgess, Sourat Darabi, Nancy Ann Dawson i in. "Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC)." Journal of Clinical Oncology 40, nr 6_suppl (20.02.2022): 287. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.287.
Pełny tekst źródłaBambury, Richard Martin, Claire Brady, Aoife McCarthy, Stewart Fleming, Nicholas J. Mayer i Derek Gerard Power. "Translocation renal cell carcinomas: An evolving entity." Journal of Clinical Oncology 30, nr 5_suppl (10.02.2012): 472. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.472.
Pełny tekst źródłaEldessouki, Ihab, Ola Gaber, Mahmoud A. Shehata, Tariq Namad, Joseph Atallah, Harsha Masineni i Nagla Abdel Karim. "Papillary renal cell carcinoma: what is missing in research? A case report and a review of literature". SAGE Open Medical Case Reports 7 (styczeń 2019): 2050313X1986947. http://dx.doi.org/10.1177/2050313x19869475.
Pełny tekst źródłaSu, Daniel, Chinonyerem Okoro, Arvin George, W. Marston Linehan i Adam R. Metwalli. "Bilateral multifocal papillary type I renal cell carcinoma: Clinical characteristics and association with chronic renal insufficiency." Journal of Clinical Oncology 32, nr 4_suppl (1.02.2014): 482. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.482.
Pełny tekst źródłaAgarwala, Vivek, Anant Ramaswamy, Amit Joshi, Vijay Maruti Patil, Vanita Noronha, Santosh Menon, B. Palak Popat, Sable Nilesh i Kumar Prabhash. "Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis". South Asian Journal of Cancer 07, nr 04 (październik 2018): 226–30. http://dx.doi.org/10.4103/sajc.sajc_22_18.
Pełny tekst źródłaEssam, Abdul Monem, Ajit Venniyoor, Suresh Nagdev, Itrat Mehdi i Bassim Al Bahrani. "Long-term survival in a case of metastatic papillary renal cell carcinoma". South Asian Journal of Cancer 06, nr 01 (styczeń 2017): 019–34. http://dx.doi.org/10.4103/2278-330x.202562.
Pełny tekst źródłaYamazaki, Haruhiko, Takeshi Kishida, Go Noguchi, Hiroyuki Iwasaki, Nobuyasu Suganuma, Katsuhiko Masudo, Hirotaka Nakayama i in. "Nephrectomy for Metastatic Kidney Tumor in Patients with Differentiated Thyroid Cancer: A Report of Two Cases". Case Reports in Endocrinology 2018 (11.11.2018): 1–5. http://dx.doi.org/10.1155/2018/7842792.
Pełny tekst źródłaVoss, Martin Henner, Yingbei Chen, Joshua Chaim, Devyn Taylor Coskey, Kaitlin Woo, Sujata Patil, Ana M. Molina, James Hsieh, Robert J. Motzer i Darren Richard Feldman. "A phase II trial of everolimus and bevacizumab in advanced non-clear cell renal cell cancer." Journal of Clinical Oncology 33, nr 7_suppl (1.03.2015): 411. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.411.
Pełny tekst źródłaLam, J. S., R. H. Goel, A. J. Pantuck, R. A. Figlin i A. S. Belldegrun. "Long-term survival following nephrectomy for renal cell carcinoma: The 15 year University of California-Los Angeles experience". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 14532. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.14532.
Pełny tekst źródłaPeters, Inga, Christel Reese, Natalia Dubrowinskaja, Wiebke Inga Antonopoulos, Martin Krause, Tu Nghi Dang, Alexander Grote i in. "DNA methylation signature for the assessment of metastatic risk in primary renal cell cancer." Journal of Clinical Oncology 35, nr 6_suppl (20.02.2017): 516. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.516.
Pełny tekst źródłaChoueiri, Toni K., Anne Plantade, Paul Elson, Sylvie Negrier, Alain Ravaud, Stephane Oudard, Ming Zhou, Brian I. Rini, Ronald M. Bukowski i Bernard Escudier. "Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma". Journal of Clinical Oncology 26, nr 1 (1.01.2008): 127–31. http://dx.doi.org/10.1200/jco.2007.13.3223.
Pełny tekst źródłaVoss, Martin H., Ana M. Molina, Ying-Bei Chen, Kaitlin M. Woo, Joshua L. Chaim, Devyn T. Coskey, Almedina Redzematovic i in. "Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non–Clear Cell Renal Cell Carcinoma". Journal of Clinical Oncology 34, nr 32 (10.11.2016): 3846–53. http://dx.doi.org/10.1200/jco.2016.67.9084.
Pełny tekst źródłaPower, Derek Gerard, Jodie E. Battley, Aoife McCarthy, Claire Brady, John P. Sweeney, Stewart Fleming, Nicholas J. Mayer i Richard Martin Bambury. "Translocation renal cell carcinomas: An evolving entity." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): e15078-e15078. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15078.
Pełny tekst źródłaTsimafeyeu, Ilya, Alexandra Naumova, Evgenia Stepanova, Alfia Khasanova, Ilya Varlamov, Nigel Wynn, Anton Snegovoy i Lev V. Demidov. "FGFR2 expression to predict survival outcome in patients with metastatic papillary renal cell carcinoma." Journal of Clinical Oncology 34, nr 2_suppl (10.01.2016): 506. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.506.
Pełny tekst źródłaNicaise, Edouard, Benjamin Schmeusser, Adil Ali, Eric Midenberg, Arnold Raul Palacios, Ethan Kearns, Sriram Ambadi i in. "Linear muscle segmentation for metastatic renal cell carcinoma." Journal of Clinical Oncology 42, nr 4_suppl (1.02.2024): 380. http://dx.doi.org/10.1200/jco.2024.42.4_suppl.380.
Pełny tekst źródłaMorinaga, Ryota, Takashi Kawahara, Yasuhide Miyoshi, Masahiro Yao i Hiroji Uemura. "Longer Control of Nivolumab in Metastatic Renal Cell Carcinoma Patients with End-Stage Kidney Disease on Dialysis". Case Reports in Oncology 12, nr 2 (6.08.2019): 608–12. http://dx.doi.org/10.1159/000501768.
Pełny tekst źródłaAlbiges, Laurence, Daniel Yick Chin Heng, Jae-Lyun Lee, Stephen Walker, Anders Mellemgaard, Lone Ottesen, Melanie M. Frigault i in. "MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): e19321-e19321. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19321.
Pełny tekst źródłaMoreira, Raphael Brandao, Rana R. McKay, Wanling Xie, Daniel Yick Chin Heng, Guillermo de Velasco, Daniel E. Castellano, Andre Poisl Fay i in. "Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC)." Journal of Clinical Oncology 35, nr 6_suppl (20.02.2017): 482. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.482.
Pełny tekst źródłaHeng, Daniel Y. C., i Toni K. Choueiri. "Non–Clear Cell Renal Cancer: Features and Medical Management". Journal of the National Comprehensive Cancer Network 7, nr 6 (czerwiec 2009): 659–65. http://dx.doi.org/10.6004/jnccn.2009.0046.
Pełny tekst źródłaBodard, Sylvain, Idris Boudhabhay, Charles Dariane, Christophe Delavaud, Sylvain Guinebert, Dominique Joly, Marc-Olivier Timsit i in. "Percutaneous Thermal Ablation for Renal Tumors in Patients with Birt–Hogg–Dubé Syndrome". Cancers 14, nr 20 (11.10.2022): 4969. http://dx.doi.org/10.3390/cancers14204969.
Pełny tekst źródłavon Klot, Christoph A. J., Natalia Dubrowinskaja, Jörg Hennenlotter, Mario W. Kramer, Axel S. Merseburger, Arnulf Stenzl, Inga Peters, Hossein Tezval, Markus A. Kuczyk i Juergen Serth. "Rho GDP dissociation inhibitor beta ARHGDIB in renal cell cancer." Journal of Clinical Oncology 33, nr 7_suppl (1.03.2015): 474. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.474.
Pełny tekst źródłaTsimafeyeu, I., A. Khasanova, E. Stepanova, M. Gordiev, D. Khochenkov, A. Naumova, I. Varlamov, A. Snegovoy i L. Demidov. "FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma". Clinical and Translational Oncology 19, nr 2 (5.07.2016): 265–68. http://dx.doi.org/10.1007/s12094-016-1524-y.
Pełny tekst źródłaSawyer, Reed, i Harris Wayne B. "Clinical implications of epigenetics in Renal Cell Carcinoma". Archives of Renal Diseases and Management 7, nr 1 (27.07.2022): 008–13. http://dx.doi.org/10.17352/2455-5495.000040.
Pełny tekst źródłaMarchand Crety, Charles, Estelle Vigneau i Camille Invernizzi. "Stereotactic Body Radiotherapy of a Solitary Metachronous Sphenoid Metastasis from Renal Cell Cancer: A Case Report". Case Reports in Oncology 14, nr 1 (2.03.2021): 269–73. http://dx.doi.org/10.1159/000513743.
Pełny tekst źródłaAhrens, Marit, Bernard Escudier, John B. A. G. Haanen, Ekaterini Boleti, Marine Gross Goupil, Marc-Oliver Grimm, Sylvie Negrier i in. "A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): TPS4597. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps4597.
Pełny tekst źródłaAhrens, Marit, Bernard Escudier, Ekaterini Boleti, Marc-Oliver Grimm, Marine Gross-Goupil, Philippe Barthelemy, Gwenaelle Gravis i in. "A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): TPS5103. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps5103.
Pełny tekst źródłaCasuscelli, Jozefina, Andrew G. Winer, Eduard Reznik, Jianing Xu, Brandon Manley, Jyoti Chouhan, Victor E. Reuter i in. "Single-institutional analysis of patients with clear-cell papillary renal cell carcinoma." Journal of Clinical Oncology 34, nr 2_suppl (10.01.2016): 512. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.512.
Pełny tekst źródłaGrenader, Tal, Eli Rosenbaum, Sofia Zilber, Naama Bogot i Linda Shavit. "Spontaneous Regression of Metastatic Papillary Renal Cell Cancer After Cessation of Treatment With Sorafenib". Clinical Genitourinary Cancer 11, nr 2 (czerwiec 2013): 201–3. http://dx.doi.org/10.1016/j.clgc.2012.11.005.
Pełny tekst źródłaPrager, Gerald, i Marina Poettler. "CD98hc expression to predict prognosis in renal cell cancer." Journal of Clinical Oncology 30, nr 30_suppl (20.10.2012): 26. http://dx.doi.org/10.1200/jco.2012.30.30_suppl.26.
Pełny tekst źródła